Antimicrosomal antibodies: What are they telling us? by Watkins, Paul B.
Vol. 13, No. 2, 1991 HEPATOLOGY Elsewhere 385 
8. Nguyen LB, Shefer S, Salen G, et al. Purification of cholesterol 7 
a-hydroxylase from human and rat liver and production of 
inhibiting polyclonal antibodies. J Biol Chem 1990;265:4541-4546. 
9. Jelinek DF, Russell DW. Structure of the rat gene encoding 
cholesterol 7 a-hydroxylase. Biochemistry 1990;29:7781-7785. 
10. Noshiro M, Okuda K. Molecular cloning and sequence analysis of 
cDNA encoding human cholesterol 7 a-hydroxylase. FEBS Lett 
11. Dietschy JM. The origins, genetics, and diseases of Mexican 
1990;268:137-140, 
Americans. Am J Med Sci 1991 (in press). 
ANTIMICROSOMAL ANTIBODIES: WHAT ARE THEY 
TELLING US? 
Bourdi M, Larrey D, Nataf J,  Bernuau J, Pessayre 0, 
Iwasaki M ,  Guengerich FP, et al. Anti-liver endoplasmic 
reticulum autoantibodies are directed against human 
cytochrome P-45OIA2: a specific marker for dihy- 
dralazine-induced hepatitis. J Clin Invest 1990;85: 
1967-1973. 
EDITOR’S ABSTRACT 
Patients with dihydralazine hepatotoxicity have 
been found to have circulating autoantibodies that 
react with liver microsomes (anti-liver microsome 
antibodies) and that are clearly distinct from anti-liver 
and kidney microsomal antibodies observed in patients 
with tienilic acid-induced hepatitis and in some pa- 
tients with autoimmune hepatitis. The authors show 
that anti-liver microsome antibodies present in the 
sera of five patients with dihydralazine-induced hepa- 
titis specifically react on immunoblots with a 53 kD 
protein. They further conclude that this target antigen 
is the phase I drug metabolizing enzyme termed 
P-45OIA2 based on the following observations: (a) 
immunoblots of a battery of human liver microsomes 
produced the identical pattern of relative staining 
whether the blots were developed with anti-rat 
P-45OIA2 IgG, anti-human P-450LA2 IgG or each of the 
five patients’ sera; (b) P-45OIA2 catalytic activity was 
selectively inhibited when human liver microsomes 
were preincubated with anti-liver microsome-positive 
sera; (c) anti-liver microsome-positive sera identified 
purified human P-45OM on immunoblots. Anti-liver 
microsome antibodies appeared to be specific for 
dihydralazine hepatitis because they were not present 
in sera obtained from 28 other patients including 
patients receiving dihydralazine without a toxic re- 
sponse and patients with other significant liver dis- 
eases. Finally, the authors demonstrated that dihy- 
dralazine could competitively inhibit catalytic activity 
characteristic of P-45OM in human liver microsomes, 
suggesting that P-45OIA2 may be involved in the 
metabolism of dihydralazine. 
COMMENTS 
When we order serum antimitochondrial antibody, 
antinuclear antibody or antiparietal cell antibody tests 
on our patients, the test is usually performed by applying 
serial dilutions of the patient’s serum to a commercially 
prepared microscope slide containing sections of rodent 
liver, kidney and stomach. To the trained eye, the 
immunofluorescent patterns produced by each type of 
autoantibody are diagnostic. Rarely, the serum from a 
patient will react with liver and kidney endoplasmic 
reticulum; these organelles can be isolated from whole 
tissue as tiny membrane vesicles termed microsomes. 
The antibodies that react with endoplasmic reticulum 
are therefore called liverkidney microsomal, or LKM, 
antibodies. Although all microsomal antibodies produce 
similar immunofluorescent patterns in the liver tissue, 
it has been possible to distinguish two types of anti-LKM 
antibodies: those reacting most intensely with renal cells 
in the distal third of the proximal tubules (called LKM1) 
and those reacting most intensely with the cells in the 
initial third of the tubule (called LKM2). Anti-LKM1 
antibodies have been observed in some patients with 
halothane hepatitis and appear to also identify a sub- 
group of patients with severe autoimmune hepatitis. 
Anti-LKM2 antibodies have been observed in patients 
with tienilic acid-induced hepatitis and appear to be 
relatively specific markers of this condition. The paper 
by Bourdi et al. deals with a third type of antimicrosomal 
antibodies that do not react with kidney tissue at all and 
are therefore called anti-liver microsomal (anti-LM) 
antibodies. To date, this immunofluorescent pattern has 
only been observed using sera from patients who have 
dihydralazine-induced hepatitis and, recently, from one 
child with autoimmune hepatitis (1). 
The investigators convincingly demonstrate that the 
major antigen recognized by the anti-LM antibodies in 
sera from five patients is a cytochrome P-450 (P- 
450IA2). They also show that P-450IA2 binds and 
presumably metabolizes dihydralazine. This is the 
second type of drug-induced liver disease to be associated 
with autoantibodies to specific cytochromes P-450 (P- 
450s). Patients with tienilic acid-induced hepatitis 
usually have serum antibodies (anti-LKMB) that rec- 
ognize another P-450 (P-450IIC8/9) (2). In this case as 
well, the antibody appears to recognize a P-450 involved 
in the metabolism of tienilic acid (2). The simplest 
explanation for these autoantibodies (2) is that the 
metabolites produced by P-450s from dihydralazine and 
tienilic acid are so unstable that they react with, and 
antigenically alter, the P-450 proteins that produced the 
metabolites. This is a reasonable hypothesis because 
P-450s have been shown to convert many substrates to 
reactive metabolites capable of covalently binding cel- 
lular proteins (3). Moreover, the P-450s should be 
convenient targets for the metabolites because they are 
likely to be the proteins nearest to the metabolites as 
they are produced. 
Reactive metabolites can cause hepatotoxicity by 
binding to, or reacting with, proteins whose functions 
are vital to the hepatocyte (3). The reaction of metabo- 
lites with P-45OIA2 and P-450IIC8/9 should not directly 
cause toxicity because these enzymes are unlikely to be 
of critical importance to the hepatocytes. However, it 
seems reasonable to assume that the P-450s would not 
be the only protein targets for reactive metabolites, some 
of which might be more crucial for hepatocyte survival. 
If metabolites are directly causing the drug toxicity 
observed, the production of antibodies to  the P-450s 
might be occurring only after hepatocytes have lysed; 
this would explain why anti-LM antibodies were ob- 
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served only in patients with dihydralazine hepatitis and 
not in all patients treated with the drug. In other words, 
the presence of anti-P-450 antibodies could be incidental 
and merely imply that toxicity is the direct result of 
reactive metabolite(s1 produced by the P-450 recognized 
by the antibody. The fact that only a small fraction of 
patients receiving the drug develop toxicity may reflect 
the recognized interpatient differences in the catalytic 
activities of the P-450s or detoxifying enzymes (3). 
A more exciting possibility is that antimicrosomal 
antibodies may directly contribute to the pathogenesis of 
some forms of liver disease. Data supporting this view 
are indirect and largely obtained from studies of 
halothane hepatitis (4). Anti-LKM1 antibodies are often 
present in sera of patients with halothane hepatitis. 
These antibodies will react with hepatocytes isolated 
from halothane-pretreated rabbits and will also activate 
the destruction of the hepatocytes by lymphocytes 
in uitro. It appears that the major hepatocyte proteins 
recognized by these antibodies have become antigenic by 
covalently binding the trifluoroacetyl metabolite of 
halothane produced by P-450(s). One trifluoroacetylated 
protein has the molecular weight of a P-450 and is 
postulated to be the P-450 that produces trifluoroacetyl 
chloride. A second protein identified is a carboxyl 
esterase, which is a major protein present in the 
endoplasmic reticulum (5). This enzyme is unlikely to be 
involved in metabolism of halothane and may therefore 
become trifluoroacetylated as an “innocent bystander.” 
Trifluoroacetylated proteins are not confined to  the 
endoplasmic reticulum; they also appear to be present on 
the surface membrane of halothane-treated hepato- 
cytes. P-450s and other microsomal proteins may be 
present on the hepatocyte membrane (6) but need not be 
the antigens stimulating an immune attack. This is 
because the majority of proteins present on the surface 
of the hepatocyte are synthesized in ribosomes bound to 
the hepatocyte’s endoplasmic reticulum. Thus proteins 
could be trifluoracetylated immediately after synthesis 
and before they are sorted to the plasma membrane. 
This idea is supported by studies of isaxonine, which is 
converted to  a reactive metabolite in the endoplasmic 
reticulum. When 14C isaxonine was administered to rats 
in uiuo, radiolabeled protein was detected first in 
endoplasmic reticulum and subsequently in the plasma 
membrane (7). In uztro metabolism of 14C isaxonine in a 
mixture of liver microsomes and plasma membranes 
(which were attached to beads) resulted in radiolabeling 
of microsomal proteins, but there was little labeling of 
plasma membrane proteins (7). These studies suggest 
that a metabolite of isaxonine capable of covalent 
binding does not diffuse far from its site of production 
within the endoplasmic reticulum, presumably because 
it is extremely reactive. Proteins bound to the metabolite 
presumably appear in the surface membrane of the 
hepatocyte after the binding has occurred within the 
endoplasmic reticulum (7). 
By analogy to the current thoughts about halothane 
hepatitis, antimicrosomal antibodies may indicate that 
reactive metabolites capable of creating neoantigens are 
being produced in the endoplasmic reticulum; some of 
these neoantigens could reasonably end up on the 
surface membrane and stimulate an immune attack in 
an “allergic” individual. An antibody directed to a 
specific P-450 probably identifies the enzyme respon- 
sible for generating the reactive metabolite but need not 
imply that this antibody is directly involved in an 
immune attack on the liver. 
It may be argued that observations made in halothane 
hepatitis, which has clinical features suggesting hyper- 
sensitivity, are not relevant to other drugs, such as 
tienilic acid and dihydralazine, which generally produce 
hepatitis in the absence of the classic clinical hallmarks 
of hypersensitivity (skin rash, fever and eosinophilia). 
However, hepatotoxicities caused by many drugs have at 
least some features consistent with an immunological 
basis. For example, although tienilic acid hepatitis 
generally occurs months after patients have started 
therapy, it often recurs within 24 hr after patients who 
have recovered from the toxicity are rechallenged with 
the drug (8). Hepatitis also develops sooner on rechal- 
lenge in patients who have recovered from dihydralazine 
hepatitis (9). Finally, it should also be remembered that 
patients with autoimmune hepatitis do not generally 
exhibit skin rashes, fever or eosinophilia, although an 
immunological basis for this disease is accepted. The 
absence of the classic clinical signs of hypersensitivity 
therefore do not in itself exclude the possibility that 
autoimmunity is playing a role in the pathogenesis of 
drug-induced liver disease. 
In summary then, the findings of Bourdi et al. are 
important because they support the idea that anti-P-450 
antibodies (a) indicate that reactive metabolites are 
being produced in the liver that are capable of altering 
protein structure and creating new antigens and (b) 
point to which P-450 is producing these metabolites. The 
observed injury may be the direct result of the reactive 
metabolites, it may be the result of immune responses to 
new antigens formed as a result of the metabolites or 
both mechanisms could be involved. As a final point, 
anti-LKM1 antibodies observed in a subset of patients 
with generally severe autoimmune hepatitis have been 
shown to selectively identify P-450IID and several other 
microsomal antigens (10, 11). Recently, a child with 
autoimmune hepatitis has been shown to have anti-LM 
antibodies recognizing P-45OIA2 (11, the identical an- 
tigen identified by anti-LM antibodies in dihydralazine- 
induced hepatitis. Although drugs do not appear to be 
involved in autoimmune hepatitis, many substances en- 
countered in our diet appear to be metabolized by P-450s 
(3). The observations made in hepatitis caused by tienilic 
acid and dihydralazine support the hypothesis that some 
forms of autoimmune hepatitis may result when re- 
active, neoantigen-forming metabolites are produced 
from dietary substances by P-450s (10). If this is so, it 
may be possible to identify and remove potential of- 
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fending compounds from the diet of these individuals. 
Alternately, the administration of selective inhibitors of 
the P-450s identified by the autoantibodies might pro- 
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EPIDEMIOLOGICAL STUDIES WITH 
ANTI-HEPATITIS C VIRUS 
Stevens CE, Taylor PE, Pindyck J, Choo Q-L, Bradley 
OW, Kuo G, Houghton M. Epidemiology of hepatitis C 
virus: a preliminary study in volunteer blood donors. 
JAMA 1990;263:49-53. 
ABSTRACT 
In a survey carried out from 1985 through 1986, 
volunteer blood donors to The Greater New York Blood 
Program were tested for two surrogate markers for 
non-A, non-B hepatitis- elevation of alanine ami- 
notransferase level and presence of antibody to hepa- 
titis B core antigen. Stored serum samples from se- 
lected donors were also recently tested for antibody to 
hepatitis C virus (anti-HCV). Anti-HCV was detected in 
0.9% to 1.4% of donors and was higher in black and 
Hispanic donors than in white donors. Anti-HCV prev- 
alence increased with increasing age through the 
fourth decade of life, but decreased thereafter, possibly 
reflecting the disappearance of detectable antibody 
with time. Anti-HCV correlated with both alanine 
aminotransferase level and the presence or absence of 
antibody to hepatitis B core antigen. These associa- 
tions suggest that donor screening for elevation of 
alanine aminotransferase level and presence of an- 
tibody to hepatitis B core antigen was, as expected, at 
least partially effective in preventing transfusion- 
associated non-A, non-B hepatitis. The detection of 
anti-HCV in donors who have neither an elevation of 
alanine aminotransferase level nor presence of an- 
tibody to hepatitis B core antigen suggests that donor 
screening for anti-HCV will further reduce the risk of 
transfusion-associated hepatitis. 
COMMENTS 
The search for a viral agent in patients with non-A, 
non-B hepatitis (NANBH) after transfusion has been 
long and difficult. Hundreds of putative agents and tests 
have been proposed, evaluated and then discarded when 
it became clear that each lacked the requisite specificity. 
In 1985 Bradley did identify and characterize a small 
enveloped virus that was readily transmissible to chim- 
panzees (11, but it remained for Michael Houghton and 
his coworkers a t  the Chiron Corporation to take the next 
major step forward (2). They used a molecular biological 
approach to identify a clone that encoded €or a poly- 
peptide associated with NANBH. The polypeptide was 
then synthesized in recombinant yeast and used as the 
basis of an assay for antibodies to at least one major 
etiological virus of NANBH. 
The availability of a test for anti-hepatitis C virus 
(anti-HCV) has opened new vistas for hepatologists 
throughout the world. As this new test is applied to 
patients with (and without) liver disease, some long- 
standing problems surely will be resolved. Certainly, at 
the same time new ones will be uncovered. 
From early studies we have learned that a high 
proportion of patients with documented NANBH after 
transfusion are anti-HCV positive (3). There is a high 
prevalence of anti-HCV in intravenous drug abusers, 
hemophiliacs and hemodialysis patients and a somewhat 
lower prevalence in homosexual men. This later finding 
was unexpected, as was the high prevalence in patients 
with autoimmune CAH and cirrhosis. About 1% of 
healthy blood donors are also anti-HCV positive. 
In the paper under discussion here, Stevens and her 
coworkers have begun the important task of large-scale 
epidemiological studies designed to learn about this 1% 
of the population. They have analyzed a selected sample 
of blood donors from New York City, which has shed 
